Search Results
Your search for Philip matches 162 pages
Showing 1 - 50Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphomas of B cells and T cells. We now know DLBCL is still heterogenous and some subtypes might benefit...
Link Between CT Scans and Future Cancer Incidence?
At current use and radiation dose levels, computed tomography (CT) scans may eventually account for 5% of all cancers annually, according to a recent modeling study published by Smith-Bindman et al in JAMA Internal Medicine. The danger is greatest for infants, followed by children and...
Influence of Social Networks Among Older Patients With Cancer
Researchers have received a $3.5 million grant from the National Cancer Institute to examine the impact of social networks on the decision-making process among older patients with cancer. Background Many individuals have social networks, which includes those who offer a connection and have similar...
Impact of Prevention and Screening on Mortality From Five Common Cancers
Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study led by researchers at the National Institutes of Health (NIH). The study, published by Goddard et al in JAMA...
Genitourinary Cancer Expert Yüksel Ürün, MD, Shares His Career Journey and the Importance of Achieving a Work/Life Balance
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD, about his clinical and research career in oncology. Dr. Ürün is Professor of Medicine at the Ankara University School of Medicine in Turkey. After...
New Insights Into Innate Resistance for Immunotherapies in Colorectal Cancer
Researchers have assessed the efficacy of targeting the CD47 protein combined with traditional immunotherapy drugs in patients with colorectal cancer, with a recent study published by Arai et al in the Journal for ImmunoTherapy of Cancer. The findings indicated that the combination approach could...
Metastatic Pancreatic Adenocarcinoma: Addition of Devimistat to mFFX
As reported in the Journal of Clinical Oncology, Philip et al found that the phase III AVENGER 500 study showed no overall survival benefit with devimistat plus modified fluorouracil, oxaliplatin, irinotecan, and leucovorin (mFFX) vs FFX in patients with metastatic pancreatic adenocarcinoma. As...
A Mother’s Encouragement and a Husband-Wife Doctor Team Set the Stage for a Career in Hematologic Oncology
Lymphoma expert Jane N. Winter, MD, grew up on the south shore of Long Island in New York. “My dad sold cars in my great uncle’s dealership after a failed foray into business after World War II. My mom graduated high school at 16 to go to work to help support her family. When my younger brother...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past dozen years, many in the oncology community have been profiled in this special issue. A complete list of individuals...
AACR Inaugurates New Leadership
The members of the American Association for Cancer Research (AACR) elected a new 2024 to 2025 President and President-Elect at the AACR’s Annual Business Meeting of Members during the AACR Annual Meeting 2024 in San Diego. New President The AACR welcomed Patricia M. LoRusso, DO, PhD (hc), FAACR, as ...
ASCO Congratulates 2024 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2024 ASCO Annual Meeting. The 2024 Special Award Recipients...
Benefit of Prostate MRI Plus PSA Density Test in Patients Suspected of Having Prostate Cancer
Investigators have found that combining a prostate magnetic resonance imaging (MRI) scan with a prostate-specific antigen (PSA) density test may help diagnose clinically significant prostate cancer and avoid unnecessary biopsies, according to a recent systematic review and meta-analysis published...
From a Small Town in Lebanon, a Young Doctor Follows His Passion to an International Career in Cancer Research
Philip A. Salem, MD, Director Emeritus of Cancer Research at St. Luke’s Episcopal Hospital, Houston, was born and reared in Bterram, a village that overlooks the Mediterranean Sea. “I had the most beautiful and blessed childhood, as I lived in a household dominated by a father who believed in the...
AACR Annual Cancer Progress Report Highlights Scientific Advances Against Cancer, Challenges and Opportunities Ahead
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)—over the past 3 decades, coupled with advances in prevention and early detection, has led to a 33% reduction in cancer...
AACR Issues Annual Cancer Progress Report
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)—over the past 3 decades, coupled with advances in cancer prevention and early detection, has led to a 33% reduction in cancer...
Loss of Y Chromosome in Men and Bladder Cancer Progression
Researchers have found that the loss of the Y chromosome, a common impact of the aging process in men, may help cancer cells evade the body’s immune system and result in aggressive bladder cancer—but it may also render the disease more vulnerable and responsive to immune checkpoint...
City of Hope to Rebrand Cancer Treatment Centers of America Locations to Reflect Transition to National System
City of Hope in Duarte, California, recently announced that its subsidiary, Cancer Treatment Centers of America (CTCA), will fully transition its clinical locations to City of Hope’s brand. CTCA locations in different cities will now be called City of Hope Atlanta, City of Hope Chicago, and City of ...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
Andrea Schietinger, PhD, to Present 2023 AACR–Irving Weinstein Foundation Distinguished Lecture
The American Association for Cancer Research (AACR) will award the 19th AACR–Irving Weinstein Foundation Distinguished Lectureship to Andrea Schietinger, PhD, during the 2023 AACR Annual Meeting, held April 14–19, in Orlando, Florida. Dr. Schietinger, an associate member of the Immunology Program...
Changing the Algorithm for Relapsed or Refractory Large B-Cell Lymphomas
Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect the limits of repeated exposure to chemotherapy, even when delivered at high doses. More than 30 years ago,...
Allison Institute Announces Creation of Scientific Advisory Board
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center, Houston, recently announced the establishment of its scientific advisory board to provide strategic guidance and evaluation of its research portfolio and programs. The 11-person advisory board will be co-chaired by ...
Philip D. Greenberg, MD, FAACR, Voted AACR President-Elect for 2022–2023
The members of the American Association for Cancer Research (AACR) have chosen Philip D. Greenberg, MD, FAACR, as the Association’s President-Elect for 2022–2023. Dr. Greenberg is the Rona Jaffe Foundation Endowed Chair and Professor and Head of the Program in Immunology, Clinical Research...
Study Examines Disparities in Relapse Among Pediatric Patients With ALL
According to a large multiethnic study presented by Sok et al at the American Association for Cancer Research (AACR) Annual Meeting 2022, Latinx children with acute lymphoblastic leukemia (ALL) and measurable residual disease (MRD)-negative status were more likely to relapse compared with...
CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas
“The mind is not a vessel to be filled but a fire to be kindled.” —Plutarch About 30% to 40% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) experience relapse, and 10% are refractory to the...
Cancer Physician and Researcher Philip Philip, MD, PhD, to Join Henry Ford Cancer Institute
Medical oncologist Philip A. Philip, MD, PhD, has joined Henry Ford Cancer Institute (HFCI) as Director of Gastrointestinal Oncology and Neuroendocrine Oncology, Medical Director of Research and Clinical Care Integration, and co-leader of the Henry Ford Pancreatic Cancer Center (HFPCC). Dr. Philip...
Expert Point of View: Philip L. McCarthy, MD
The ASCO Post invited myeloma expert Philip L. McCarthy, MD, Director of the Transplant and Cellular Therapy Program at Roswell Park Comprehensive Cancer Center, Buffalo, New York, to comment on the trials evaluating early detection of myeloma at the 2021 American Society of Hematology (ASH) Annual ...
Risk-Standardized Mortality Rates as Quality Proxy for Surgical Oncology
In a German study reported in the Journal of Clinical Oncology, Baum et al found that risk-standardized mortality rates may be a better-quality proxy for complex oncologic surgeries than hospital volume. As stated by the investigators, “Despite a long-known association between annual hospital...
Philip L. McCarthy, MD, Comments on Trials Evaluating the Early Detection of Myeloma
The ASCO Post invited myeloma expert Philip L. McCarthy, MD, Director of the Transplant and Cellular Therapy Program at Roswell Park Comprehensive Cancer Center, Buffalo, New York, to comment on the trials evaluating early detection of myeloma at the 2021 American Society of Hematology (ASH) Annual ...
Tackling the Challenge of Pancreatic Cancer: New Approaches
Pancreatic cancer remains an incorrigible foe, but recent advances in genomic profiling and targeted drug development are slowly improving the outlook for patients, according to Eileen M. O’Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology and Section Head,...
Expert Point of View: Philip McCarthy, MD
Commenting on the updated results of the MAIA trial1 for The ASCO Post was Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York. Dr. McCarthy described how the...
Lessons From Pneumococcal Vaccine Responses in Patients With CLL in an Evolving Vaccine Landscape
The role of vaccines in mitigating the significant morbidity and mortality associated with infections in chronic lymphocytic leukemia (CLL) is a developing field of study, punctuated by the advent of novel therapeutic agents and pressing questions regarding the global SARS–CoV-2 vaccination...
Selected Poster Presentations From the NCCN 2021 Annual Conference
Although once again, the National Comprehensive Cancer Network® (NCCN®) 2021 Annual Conference could not take place on site in Orlando, researchers presented their work virtually in the form of almost 100 posters. The ASCO Post has summarized some that we found particularly interesting. Many...
Outcomes With Internal Mammary and Medial Supraclavicular Nodal Irradiation in Stage I to III Breast Cancer
As reported in The Lancet Oncology by Philip M. Poortmans, PhD, Department of Radiation Oncology of the Iridium Netwerk and the Faculty of Medicine and Health Sciences, University of Antwerp, and colleagues, 15-year outcomes of the phase III EORTC 22922/10925 trial show continued reduction in...
Tabaré Vázquez, Former President of Uruguay, Oncologist, and Human Rights Activist, Dies at 80
In 2006, President of Uruguay Dr. Tabaré Vázquez, a radiation oncologist by profession, enacted comprehensive antismoking legislation, eventually leading Uruguay to become the first country in Latin America to prohibit smoking in enclosed public spaces. His bold action drew the ire of international ...
Expert Point of View: Philip McCarthy, MD
Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York, found the results of the DREAMM-6 study to be “exciting and promising.” He commented: “The overall response...
Reduced Breast Cancer Mortality and Risk of Recurrence With Internal Mammary and Medial Supraclavicular Nodal Irradiation in Stage I to III Breast Cancer
As reported in The Lancet Oncology by Philip M. Poortmans, PhD, and colleagues, 15-year outcomes of the phase III EORTC 22922/10925 trial show continued reductions in both breast cancer mortality and recurrence with postsurgery internal mammary and medial supraclavicular (IM-MS) lymph node chain...
Study Indicates Delaying Antiviral Treatment May Boost Immunity in Stem Cell Transplant Recipients
A team of cellular-therapy specialists from Roswell Park Comprehensive Cancer Center has found that patients who develop cytomegalovirus (CMV) infections after allogeneic stem cell transplantation may be able to develop an immunity against the virus, strengthen their immune system, and reduce...
Expert Point of View: Philip J. Saylor, MD
Philip J. Saylor, MD, Attending Physician at Massachusetts General Hospital and Assistant Professor at Harvard Medical School, Boston, commented on this study. “The results presented are clearly exciting and cause us to look forward to a likely phase III study of this strategy. The high response...
Expert Point of View: Philip A. Philip, MD, PhD, FRCP
The study’s invited discussant, Philip A. Philip, MD, PhD, FRCP, Professor of Oncology, Pharmacology, and Medicine and the Kathryn Cramer Endowed Chair in Cancer Research at Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, asked whether another triplet regimen was...
Expert Point of View: Philip McCarthy, MD
Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York, found the results of the DREAMM-6 study to be “exciting and promising.” He commented: “The overall response...
Expert Point of View: Philip McCarthy, MD
Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York, found the results of the DREAMM-6 study to be “exciting and promising.” He commented: “The overall response...
Woman With an Ovarian Tumor
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era: 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
What Have I Learned in More Than Half a Century in Cancer Medicine?
My journey in cancer medicine started in June 1968, when I traveled from Lebanon to New York to begin my fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Since then, and on a daily basis, I have been actively engaged in the treatment of patients with cancer and in cancer...
Expert Point of View: Philip J. Saylor, MD
Philip J. Saylor, MD, Attending Physician at Massachusetts General Hospital and Assistant Professor at Harvard Medical School, Boston, commented on this study. “The results that were presented are clearly exciting and cause us to look forward to a likely phase III study of this strategy. The high...
ASCO Endorses Cancer Care Ontario Guideline on Bone Health and Bone-Targeted Therapies for Prostate Cancer
ASCO recently endorsed the Cancer Care Ontario (CCO) guideline “Bone Health and Bone-Targeted Therapies for Prostate Cancer,” which was originally approved by CCO in 2017.1 The recommendations were based on a systematic review and meta-analysis of relevant research and clinical trial reports...
Expert Point of View: Andrea Wang-Gillam, MD, PhD
Andrea Wang-Gillam, MD, PhD, Clinical Director of the GI Oncology Program and Director of Developmental Therapeutics at Washington University in St. Louis, was the invited discussant of SEQUOIA and HALO 109-301. She tried to make sense of the two negative studies of pegylated agents in advanced...
Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR-Mutant Lung Cancers
Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR-Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer. The Chen-Huang Center is being established with a $5 million gift from...
AACR Announces 2019 Class of Fellows of the AACR Academy
The American Association for Cancer Research (AACR) recently announced its newly elected class of Fellows of the AACR Academy. The mission of the AACR Academy is to recognize and honor distinguished scientists whose scientific contributions have propelled innovation and progress against cancer. The ...
How the ASCO Breakthrough Global Summit Is Bringing Together Innovators to Transform Cancer Care
Earlier this year, ASCO announced plans for its first-ever international meeting, ASCO Breakthrough: A Global Summit for Oncology Innovators, which will be held October 11–13, 2019, in Bangkok, Thailand. The meeting is a joint effort by ASCO and the Thai Society of Clinical Oncology to bring...
Shared Decision-Making in Lung Cancer Screening: Whence? Whither?
We read with interest a recent article published on ASCOPost.com, which summarized a paper on the role of shared decision-making in lung cancer screening.1,2 The summary and original report highlight a mandate by the Centers for Medicare & Medicaid Services (CMS) that bears careful...
